ClinicalTrials.gg
Active, not recruitingNCT05235516AK104-305Updated Aug 13, 2024

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

A Phase 3 interventional study of AK104 and EBRT in Locally Advanced Cervical Carcinoma, sponsored by Akeso. Active, not recruiting at 9 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer

02

Conditions studied

  • Locally Advanced Cervical Carcinoma
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signs the written form
  2. 0-1
  3. ≥ 3 months.
  4. The histological types include squamous cell carcinoma,adenocarcinoma, or adenosquamous cell carcinoma;
  5. Locally advanced cervical cancer (LACC): The International Federation of Gynecology and Obstetrics (FIGO) 2018 Stage 3A-4A
  6. At least one measurable tumor lesion per v1.1
  7. Adequate organ function as assessed in the laboratory tests

Exclusion criteria

Exclusion Criteria:

  1. Subjects with other histopathological types of cervical cancer, such as small cell carcinoma, sarcoma, etc.
  2. FIGO 2018 IVB
  3. Subjects who had previously undergone total hysterectomy
  4. Subjects who cannot receive brachytherapy
  5. Subjects with other active within 2 years prior to randomization
  6. hydronephrosis that cannot be relieved by nephrostomy or ureteral stenting as judged by the Investigator
  7. Any prior treatments targeting the mechanism of tumor immunity, such as (e.g., anti-PD-1 antibody, anti-PDL1 antibody, anti-CTLA-4 antibody, etc.), or therapy against immune costimulatory factors (e.g., antibodies directed against ICOS, 0,CD137, GITR, OX40 targets, etc).
  8. Subjects who require systemic treatment with (>10 mg/day of prednisone or equivalent glucocorticoid) or other agents within 14 days prior to randomization;
  9. Major surgical treatment, open or significant trauma within 4 weeks prior to randomization; or elective major surgical treatment required during the study
  10. Use of within 4 weeks prior to randomization
  11. Active or potentially recurrent disease
  12. Known primary or secondary immunodeficiencies, including testing positive for (HIV) antibodies
  13. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation
  14. Known history of interstitial lung disease or non-infectious pneumonitis
  15. Pregnant or lactating women.
  16. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
636 participants (estimated)

Study arms

  • Experimental
    treatment arm

    Drug: AK104 · Radiation: EBRT · Radiation: BT · Drug: cisplatin

  • Placebo comparator
    placebo arm

    Radiation: EBRT · Radiation: BT · Drug: cisplatin · Drug: Placebo

Interventions

  • DrugAK104

    q3w iv

  • RadiationEBRT

    45-50.4Gy

  • RadiationBT

    ≥80Gy

  • qw iv

  • DrugPlacebo

    q3w iv

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival(PFS) by investigator(INV)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1 and/or biopsy

    Time frame: 54 months

Secondary outcomes

  1. PFS rate at month 36

    PFS rate at month 36

    Time frame: 36 months

  2. Overall Survival(OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: 5 years

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for May 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 11, 2022
StartActual
Jun 21, 2022
Primary completionEst.
May 2026
CompletionEst.
May 2029
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05235516
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Feb 11, 2022
Start date
Jun 21, 2022
Primary completion
May 2026 (estimated)
Completion
May 2029 (estimated)
Last update
Aug 13, 2024

Study contacts

Jihong Liu, Ph.D
principal investigator · Sun Yat-sen University
Yang Xiang, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion